Literature DB >> 8590778

N-ras and p53 gene mutations are very rare events in multiple myeloma.

Y Yasuga1, S Hirosawa, K Yamamoto, J Tomiyama, K Nagata, N Aokia.   

Abstract

The frequencies of p53 and N-ras gene mutations were examined in multiple myeloma. DNA samples of 45 cases of multiple myeloma were obtained from stored bone marrow smears. All samples were analyzed for the N-ras gene at codon 12 by the allele specific restriction analysis method and at codon 61 by direct sequencing. DNA was screened for mutations by single-strand conformation polymorphism analysis for the p53 gene in exons 5 to 8. DNA fragments showing an altered electrophoretic pattern were further studied by direct sequencing to confirm the mutations. Ras mutations were found in two cases at codon 61 (4.4%). A point mutation of the p53 gene was detected in one of 45 cases (2.2%). These 3 cases with mutations were in an advanced stage. In conclusion, N-ras and p53 gene mutations may occur at a late stage of multiple myeloma, but the frequencies of the mutations are very low.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8590778     DOI: 10.1016/0925-5710(95)00394-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  3 in total

1.  p53 gene mutations in multiple myeloma.

Authors:  R G Owen; S A Davis; J Randerson; A C Rawstron; F Davies; J A Child; A S Jack; G J Morgan
Journal:  Mol Pathol       Date:  1997-02

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

Authors:  Wei Xiong; Xiaosong Wu; Sarah Starnes; Sarah K Johnson; Jeff Haessler; Siqing Wang; Lijuan Chen; Bart Barlogie; John D Shaughnessy; Fenghuang Zhan
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.